High mobility group nucleosomal binding domain 2 pseudogene 46 (HMGN2P46)

**High mobility group nucleosomal binding domain 2 pseudogene 46 (HMGN2P46)** is not an active therapeutic target but a pseudogene, meaning it is a non-protein-coding DNA sequence derived from a protein-coding gene (HMGN2) that has lost its ability to encode a functional protein. HMGN2P46 is prostate-specific and androgen-repressed, and fusions involving HMGN2P46 have been reported in prostate cancer. It may function as a competing endogenous RNA (ceRNA) or microRNA "sponge," regulating the expression of the functional HMGN2 gene by sequestering microRNAs such as miR-590-3p, thereby affecting inflammatory processes and potentially contributing to disease mechanisms. HMGN2P46 has no demonstrated role as a drug target, does not encode a receptor, enzyme, or transporter, and has no established interaction with therapeutic agents. It is sometimes referred to as Putative Dresden prostate carcinoma protein 2, but the actual protein-coding capacity is not supported, further confirming its annotation as a pseudogene[1][2][4][7]. **NOTES:** - HMGN2P46 is a **pseudogene**, so it is **not a canonical therapeutic target** such as a receptor, transporter, or enzyme[4][7]. - The main biological relevance is inferred from its function as a **microRNA sponge** (ceRNA) influencing HMGN2 activity and is implicated in prostate cancer by gene fusions, but not as a direct druggable target or biomarker[1][4]. - No direct interacting drugs, mechanisms of action, or safety concerns are reported. - If a druggable target is needed, HMGN2 (the actual protein-coding high mobility group nucleosomal binding domain 2 gene) would be the relevant target, not HMGN2P46.

Other names

Putative Dresden prostate carcinoma protein 2HMGN2P46C15orf21D-PCa-2FLJ39426High mobility group nucleosome-binding domain-containing protein 2 pseudogene 46